Abstract:Peroxisome proliferator‐activated receptor alpha (PPAR‐α) is a major transcription factor that governs the expression of fatty acid oxidation (FAO) and anti‐inflammatory genes during fasting. Acyl‐CoA thioesterase 1 (ACOT1) hydrolyzes acyl‐CoAs to long‐chain free fatty acids and Coenzyme A during fasting. ACOT1 activity seemingly removes acyl‐CoA substrate for mitochondrial FAO and produces long‐chain free fatty acids that could serve as ligands to activate PPAR‐α. The objective of this research was to identify the role of ACOT1 in hepatic fasting lipid metabolism. To test our objectives, we injected C57Bl/6 mice with an adenovirus harboring shRNA targeted to ACOT1 or a scrambled control. Week‐long liver specific knockdown of ACOT1 increased FAO in vivo measured by serum β‐hydroxybutyrate and reduced liver triglyceride. These data correlated to results from in vitro fatty acid tracer studies in which ACOT1 knockdown increased FAO and triglyceride turnover. Despite increased FAO, ACOT1 knockdown reduced the expression of PPAR‐α target genes involved in FAO. In addition, ACOT1 knockdown led to increased expression of inflammatory and oxidative stress genes, due to reduced PPAR‐α dependent anti‐inflammatory signaling. Moreover, in vitro experiments exhibited increased PPAR‐α reporter activity in COS7 cells overexpressing ACOT1. The ability of ACOT1 to increase PPAR‐α activity was dependent on its catalytic activity, suggesting that ACOT1 produces fatty acids that serve as ligands for PPAR‐α. To confirm this theory, mice were supplemented with a synthetic PPAR‐α ligand, Wy‐14643, which rescued the expression of PPAR‐α target genes and mitigated the inflammation and oxidative stress observed in response to ACOT1 knockdown. Importantly, ACOT1 exhibits nuclear localization during prolonged fasting or under β‐adrenergic stimulation, suggesting a local pool of free fatty acids activate PPAR‐α.Together these studies suggest that ACOT1 coordinates the rate of fatty acid oxidation while simultaneously producing fatty acids that activate PPAR‐α, potentially in the nucleus, to protect the liver from inflammation and oxidative stress. Support or Funding Information NIH/NIDDK T32 Training grant, Minnesota Obesity Training Program Predoctoral Fellowship (DK083250), awarded to Mallory Franklin.

Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.

Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents.

Reversal of Diet-Induced Hepatic Steatosis and Hepatic Insulin Resistance by Antisense Oligonucleotide Inhibitors of Acetyl-Coa Carboxylases 1 and 2.

Liver-specific Loss of Long Chain Acyl-CoA Synthetase-1 Decreases Triacylglycerol Synthesis and β-Oxidation and Alters Phospholipid Fatty Acid Composition

Peroxisome Proliferator-Activated Receptor Γ Coactivator 1α Maintains NAD+ Bioavailability Protecting Against Steatohepatitis

Acyl‐CoA Thioesterase 1 regulates hepatic lipid metabolism and PPAR‐α signaling

A Bacteria-Derived Tetramerized Protein Ameliorates Nonalcoholic Steatohepatitis in Mice Via Binding and Relocating Acetyl-Coa Carboxylase

Continuous Fat Oxidation in Acetyl–coa Carboxylase 2 Knockout Mice Increases Total Energy Expenditure, Reduces Fat Mass, and Improves Insulin Sensitivity

GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)

Suppression of Diacylglycerol Acyltransferase-2 (DGAT2), but Not DGAT1, with Antisense Oligonucleotides Reverses Diet-Induced Hepatic Steatosis and Insulin Resistance.

The Role of Acyl-CoA Synthetase 1 in Bioactive Lipid Accumulation and the Development of Hepatic Insulin Resistance

224-OR: Antisense Oligonucleotide–Mediated Restriction of Mitochondrial Pyruvate Metabolism Limits DNL in High-Fat Fed C57BL6/J Mice

Targeting ACC for NASH resolution.

Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH

Medium-Chain Fatty Acid Reduces Lipid Accumulation By Regulating Expression Of Lipid-Sensing Genes In Human Liver Cells With Steatosis

Soraphen A, an inhibitor of acetyl CoA carboxylase activity, interferes with fatty acid elongation

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

Paradoxical activation of transcription factor SREBP1c and de novo lipogenesis by hepatocyte-selective ATP-citrate lyase depletion in obese mice

Inhibiting Cb1 Receptors Improves Lipogenesis in an in Vitro Non-Alcoholic Fatty Liver Disease Model

Positive Regulation of Acetate in Adipocyte Differentiation and Lipid Deposition in Obese Mice

Acacetin Protects against Non-Alcoholic Fatty Liver Disease by Regulating Lipid Accumulation and Inflammation in Mice